Rare Diseases

Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off

Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off

Palatin Technologies plans to start clinical trials of its ulcerative colitis therapy PL-8177 in the next three months.

The U.S. Food and Drug Administration’s decision to accept Palatin’s Investigational New Drug application for the treatment opened the door to the trials.

PL-8177 regulates a protein known as melanocortin receptor 1, which plays a role in inflammation and immune system response. A hallmark of ulcerative colitis is gut inflammation. It is also an autoimmune disease, or one in which the immune system attacks healthy tissue.

Melanocortin receptor 1 levels are higher than normal in a number of diseases. These include the two inflammatory bowel diseases — Crohn’s and ulcerative colitis — plus the kidney condition nephritis, rheumatoid arthritis and some skin disorders.

When they are at normal levels, melanocortin receptor 1 proteins…